Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia

Leukemia

Volumn 20, Issue 8, 2006, Pages 1361-1367

  Jin, J ^a,b,c   Jiang, D Z ^a,b   Mai, W Y ^a,b   Meng, H T ^a,b   Qian, W B ^a,b   Tong, H Y ^a,b   Huang, J ^a,b   Mao, L P ^a,b   Tong, Y ^a,b   Wang, L ^a,b   Chen, Z M ^b,c   Xu, W L ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Aclarubicin; Acute myeloid leukemia; Homoharritonine; Induction

Indexed keywords

ACLARUBICIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BRAIN HEMORRHAGE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INTRAOCULAR HEMORRHAGE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MYCOSIS; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; TACHYCARDIA; THROMBOCYTOPENIA; TRACHEITIS; TREATMENT OUTCOME; VOMITING;

EID: 33746105303     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404287     Document Type: Article

References (33)

1. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H et al. Cytosine arabinoside with daunorubicin or adriamycin therapy with acute myelocytic leukemia: A CALGB study. Blood 1982; 60: 454-463.
2. Berman E, Helle GR, Santorsa J, McKenzie S, Gee T, Kempin S et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
3. Wiernik PH, Banks PL, Case Jr DC, Arlin ZA, Periman PO, Todd MB et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
4. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103-1111.
5. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubincin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 1996; 88: 2841-2851.
6. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
7. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haematol 1992; 81: 170-177.
8. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R et al. Etoposide in acute non-lymphocytic leukemia. Blood 1990; 75: 27-32.
9. Ian MH, Richard FS, Anthony HG, John KHR, Keith W, Richard GG et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997; 89: 2308-2311.
10. Hwang WL, Young JH, Gau JP, Hu HT, Tsai YT. DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia. Am J Clin Oncol 1992; 15: 531-534.
11. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T et al. The Australasian Leukaemia Lymphoma Group. A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
12. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977; 12: 298-300.
13. Takemura Y, Ohnuma T, Chou TC, Okano T, Holland JF. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985; 14: 206-210.
14. Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990; 50: 2031-2035.
15. Wilkoff LJ, Dulmadge DA, Laster Jr WR, Griswold Jr DP. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 1989; 23: 145-150.
16. Fanucchi MP, Kong XR, Chou TC. Hexamethylene bisacetamide (HMBA) does not enhance the cytotoxic effects of adriamycin (ADR), 1,beta-D-arabinofuranosylcytosine (ARA-C) and harringtonine (HT) in HL-60 cells [abstract 1492]. Proc Am Assoc Cancer Res 1986; 27: 376.
17. Bian SG, Hao YS, Wang ZC. Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia. Chung Hua Nei Ko Tsa Chih 1990; 29: 225-260.
18. Takahashi I, Hara M, Uchida K, Takaoka K, Watanabe S, Lai M et al. Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside. Acta Med Okayama 1982; 36: 77-80.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-625.
20. World Health Organization. A Handbook for Reporting Results of Cancer Treatment. WHO Publications: Geneva, 1979.
21. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Tong Y, Huang J, Jin J, Ye X-J, Mong H-T, Mai W-Y et al. Clinical analysis of induction chemotherapy in adult patients with acute myeloid leukemia (in Chinese). Shi Yong Zhong Liu Za Zhi 2002; 17: 191-193.
23. Richard MS, Margaret RO, Mikkael A. Sekeres: Acute myeloid leukemia. Hematology 2004, 98-117.
24. Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 1997; 80: 2205-2209.
25. Tallman MS, Gary Gilliland D, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
26. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood 2003; 101: 64-70.
27. Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589.
28. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for acute myeloid leukemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107: 69-79.
29. He XY, Pohlman B, Lichtin A, Rybicki L, Kalaycio M. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 2003; 17: 1078-1084.
30. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984; 68: 1085-1091.
31. Warrell Jr RP, Coonley CJ, Gee TS. Homoharringtonine: An effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 1985; 3: 617-621.
32. Iwata N, Karasawa M, Omine M, Maekawa T, Suzuki T, Kawai Y. Aclarubicin-associated QTc prolongation and ventricular fibrillation. Cancer Treat Rep 1984; 68: 527-529.
33. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A et al. Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18: 989-997.